Regulatory Information
DCH AURIGA SINGAPORE
DCH AURIGA SINGAPORE
Therapeutic
Prescription Only
Formulation Information
TABLET, FILM COATED
**Dosage and administration:** _Adults (including the elderly):_ The recommended adult dosage is 200mg three times a day for as long as required. _Children:_ Not recommended for children under 12 years of age.
ORAL
Medical Information
**Uses:** Urispas is indicated for the symptomatic relief of dysuria, urgency, nocturia, vesical supra-pubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis and urethrotrigonitis. In addition, the preparation is indicated for the relief of vesico-urethral spasms due to catheterisation, cystoscopy or indwelling catheters; prior to cystoscopy or catheterisation; sequelae of surgical intervention of the lower urinary tract.
_Contra-indications:_ - Hypersensitivity to the active substance or to any of the excipients; - Gastrointestinal obstructive conditions or ileus; - Gastro-intestinal haemorrhage - Achalasia - Urinary retention - Glaucoma. - Myasthenia gravis.
G04BD02
flavoxate
Manufacturer Information
DCH AURIGA SINGAPORE
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA
Active Ingredients
Documents
Package Inserts
Urispas 200 tablet 200mg PI.pdf
Approved: April 18, 2019